Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Cardiol. 2009 Sep;32(9):E40-4. doi: 10.1002/clc.20475.

Efficacy and safety of tirofiban in high-risk patients with non-ST-segment elevation acute coronary syndromes.

Author information

  • 1Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.

Abstract

OBJECTIVE:

To evaluate the safety and efficacy of tirofiban in high risk patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) after percutaneous coronary intervention (PCI).

METHODS:

A total of 240 patients were randomized to either a tirofiban group or a control group.

RESULTS:

Compared with the control group, the platelet aggregation rate in the tirofiban group was lower (P < 0.01); the plasma levels of CK-MB and troponin I, cardiac form (cTnI) were lower (P < 0.05); ECG improved significantly (P < 0.05); the incidence of major adverse cardiac events (MACE) was lower (P < 0.05); and there was no difference in bleeding complications between the 2 groups (P = 0.1).

CONCLUSIONS:

The administration of tirofiban in high risk patients with NSTE-ACS after PCI is safe and effective.

Copyright 2009 Wiley Periodicals, Inc.

PMID:
19645039
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for John Wiley & Sons, Inc.
    Loading ...
    Write to the Help Desk